AUAUniversity

Live from AUA2023: Highlights in Advanced Prostate Cancer is a panel discussion filmed during the 2023 AUA Annual Meeting!

CME Available: https://auau.auanet.org/node/38002

Expiration Date: April, 2024

This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with advanced prostate cancer. Faculty will review the latest advances in prostate cancer including the many new FDA-approved agents, as well as existing standard therapies. Urologists will gain the ability to translate the latest scientific advances into their routine clinical practice, improving the care of men with advanced prostate cancer.

At the conclusion of the activity, participants will be able to:

1. Describe recent developments in the medical management of advanced prostate cancer.

2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.

3. Discuss clinical investigations in the treatment of advanced prostate cancer.

4. Analyze the risks and benefits of treatment for advanced prostate cancer.

5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas and Pfizer, Inc.

AstraZeneca

Merck & Co., Inc.

The Role of PARP Inhibitors in Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/38241

Release Date: May, 2023

Expiration Date: May, 2024

Based on the documented need from the most recent AUA needs assessment in advanced prostate cancer, this symposium will address the role of PARP Inhibitor treatment, as well as evidence and outcomes of PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline.

At the conclusion of this activity, participants will be able to:

1. Review recommended criteria for genetic testing of prostate cancer patients and how to interpret these tests.

2. Explain the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment.

3. Describe the role of PARP Inhibitor treatment alone and in combination with androgen receptor targeted therapies.

4. Review the evidence and outcomes on PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/SUO Guideline.

5. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial.

ACKNOWLEDGEMENT

This educational activity is supported by independent educational grants from:

Pfizer, Inc.

Complications of Vaginal Mesh

Course Director:

Kamran Sajadi, MD

Course Faculty:

Farzeen Firoozi, MD

Christopher F. Tenggardjaja, MD

Course Director: Warren T. Snodgrass, MD

Course Faculty: Nicol C. Bush, MD, MCS

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS

Co-Host: Sean Elliott, MD

Outline:

1. Are the terms “transitional urology” and “adult congenital urology” synonymous

2. What are the unique challenges in transitional urology

3. Why does spina bifida seem to dominate the transitional urology landscape

4. Exstrophy

5. Counseling pregnant women with a congenital urological condition

6. How does posterior urethral valve bladder present in adulthood

Update Series (2023) Lesson 4: Difficult Foleys and Foley Difficulties

Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information, please visit the AUA Update Series on the AUAUniversity: https://auau.auanet.org/update23

AUA2022: Evaluation and Management of Priapism

Course Director:

Martin Gross, MD

Course Faculty:

Trinity J. Bivalacqua MD, PhD

Jay Simhan, MD, FACS

Faysal A. Yafi, MD, FRCSC

This episode is brought to you by the AUA Leadership & Business Podcast Subscribe today by searching “AUA Leadership & Business” on your favorite podcast app.

Host: Jennifer Miles-Thomas, MD, FPMRS

Guest: Jaspreet S. Sandhu, MD

Modernizing Urology Care: The Current and Future State of Virtual Care in the United States

Host: Jay D. Raman, MD, FACS

Guest: Chad Ellimoottil, MD, MS

Health Equities and Variations in Advanced Prostate Cancer Care

CME Available: https://auau.auanet.org/node/37728

LEARNING OBJECTIVES:

At the conclusion of these activities, participants will be able to:

1. Identify the impact of race and cultural barriers for ethnic minorities on medical clinical care specific to advanced prostate cancer.

2. Evaluate financial toxicity as a barrier to optimal patient care specific to advanced prostate cancer.

3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from: 

Myovant Sciences LTD

Pfizer, Inc.